Evidence map›Paper›PMID 19543820›Full record

ArticleInflammation2009

Synthetic lipopeptide MALP-2 inhibits intracellular growth of Mycobacterium bovis BCG in alveolar macrophages-preliminary data.

Grit Jörgens, Franz-Christoph Bange, Peter F Mühlradt, Reinhard Pabst, Ulrich A Maus, Thomas Tschernig

Abstract read
PubMed Publisher
In one paragraph

Article in Inflammation, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Grit JörgensInstitute for Functional and Applied Anatomy, Medical School of Hannover, Hannover, Germany.
Franz-Christoph Bange
Peter F Mühlradt
Reinhard Pabst
Ulrich A Maus
Thomas Tschernig
Medizinische Hochschule Hannover · DEHelmholtz Centre for Infection Research · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Alveolar macrophages (AM) are the primary target cell of the lung for inhaled mycobacterial pathogens. We investigated the effect of the synthetic lipopeptide MALP-2 on the interaction between AM from rats and Mycobacterium bovis BCG. AM were infected with M. bovis BCG at a multiplicity of infection (MOI) of 10 and then cultured in medium alone or medium supplemented with either synthetic macrophage activating lipopeptide-2 (MALP-2), or IFN-gamma, or both. Mycobacterial CFU were counted on days 3 and 7 and cell-free supernatants were collected for cytokine measurements. Treatment of macrophages with MALP-2 led to reduced bacterial loads by day 3 and 7 post-infection and at the same time enhanced the release of TNF-alpha, IL-6 und IL-10 compared to non-stimulated, M. bovis BCG-infected AM. Macrophages co-treated with MALP-2 and IFN-gamma or IFN-gamma in the absence of MALP-2 limited the growth of M. bovis BCG only by day 3, but not day 7 post-stimulation. Our data show that MALP-2 is effective in decreasing bacterial loads in lung sentinel cells.

Indexed as

AnimalsColony Count, MicrobialCytokinesInterferon-gammaLipopeptidesLungMacrophages, AlveolarMycobacterium bovisRatsTuberculosisCytokinesInterferon-gammaLipopeptidesmacrophage stimulatory lipopeptide 2

Identifiers

PMID19543820
OpenAlexW1964726198

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.